Dysregulated Immunity and Immunotherapy after Sepsis

Implementation of protocolized surveillance, diagnosis, and management of septic patients, and of surgical sepsis patients in particular, is shown to result in significantly increased numbers of patients surviving their initial hospitalization. Currently, most surgical sepsis patients will rapidly recover from sepsis; however, many patients will not rapidly recover, but instead will go on to develop chronic critical illness (CCI) and experience dismal long-term outcomes. The elderly and comorbid patient is highly susceptible to death or CCI after sepsis. Here, we review aspects of the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome (PICS) endotype to explain the underlying pathobiology of a dysregulated immune system in sepsis survivors who develop CCI; then, we explore targets for immunomodulatory therapy.

[1]  L. Moldawer,et al.  Immunological Endotyping of Chronic Critical Illness After Severe Sepsis , 2021, Frontiers in Medicine.

[2]  P. Efron,et al.  The Hematopoietic Stem/Progenitor Cell Response to Hemorrhage, Injury, and Sepsis: A Review of Pathophysiology , 2020, Shock.

[3]  L. Moldawer,et al.  Abdominal sepsis patients have a high incidence of chronic critical illness with dismal long-term outcomes. , 2020, American journal of surgery.

[4]  B. Brumback,et al.  Older Sepsis Survivors Suffer Persistent Disability Burden and Poor Long-Term Survival , 2020, Journal of the American Geriatrics Society.

[5]  D. Gallego-Ortega,et al.  Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer , 2020, Cells.

[6]  M. D. de Groot,et al.  Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS) after Polytrauma: A Rare Syndrome with Major Consequences , 2020, Journal of clinical medicine.

[7]  L. Moldawer,et al.  Persistently increased cell-free DNA concentrations only modestly contribute to outcome and host response in sepsis survivors with chronic critical illness. , 2019, Surgery.

[8]  Marie-Pierre L. Gauthier,et al.  Myeloid-derived suppressor cell function and epigenetic expression evolves over time after surgical sepsis , 2019, Critical Care.

[9]  P. Pickkers,et al.  Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series , 2019, BMC Infectious Diseases.

[10]  S. Anton,et al.  Current Epidemiology of Surgical Sepsis: Discordance Between Inpatient Mortality and 1-Year Outcomes. , 2019, Annals of surgery.

[11]  T. Foster,et al.  Age and Sex Influence the Hippocampal Response and Recovery Following Sepsis , 2019, Molecular Neurobiology.

[12]  L. Moldawer,et al.  Persistently Elevated Glucagon-Like Peptide-1 Levels among Critically Ill Surgical Patients after Sepsis and Development of Chronic Critical Illness and Dismal Long-Term Outcomes. , 2019, Journal of the American College of Surgeons.

[13]  B. Brumback,et al.  The Development of Chronic Critical Illness Determines Physical Function, Quality of Life, and Long-Term Survival Among Early Survivors of Sepsis in Surgical ICUs* , 2019, Critical care medicine.

[14]  T. Roger,et al.  Myeloid-Derived Suppressor Cells in Sepsis , 2019, Front. Immunol..

[15]  K. Tenbrock,et al.  Reactive Oxygen Species as Regulators of MDSC-Mediated Immune Suppression , 2018, Front. Immunol..

[16]  L. Moldawer,et al.  Chronic Critical Illness and the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome , 2018, Front. Immunol..

[17]  H. Ueno,et al.  Innate Immunity in the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome and Its Implications for Therapy , 2018, Front. Immunol..

[18]  R. Hotchkiss,et al.  Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. , 2018, JCI insight.

[19]  V. Badovinac,et al.  Sepsis-Induced T Cell Immunoparalysis: The Ins and Outs of Impaired T Cell Immunity , 2018, The Journal of Immunology.

[20]  D. Gabrilovich,et al.  Myeloid-derived suppressor cells coming of age , 2018, Nature Immunology.

[21]  R. Bernabei,et al.  Circulating Mitochondrial DNA at the Crossroads of Mitochondrial Dysfunction and Inflammation During Aging and Muscle Wasting Disorders. , 2018, Rejuvenation research.

[22]  B. Brumback,et al.  Benchmarking clinical outcomes and the immunocatabolic phenotype of chronic critical illness after sepsis in surgical intensive care unit patients , 2017, The journal of trauma and acute care surgery.

[23]  Susan Gruber,et al.  Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data, 2009-2014 , 2017, JAMA.

[24]  M. Fleshner,et al.  Exosomes, DAMPs and miRNA: Features of Stress Physiology and Immune Homeostasis. , 2017, Trends in immunology.

[25]  B. Brumback,et al.  Evidence for Persistent Immune Suppression in Patients Who Develop Chronic Critical Illness After Sepsis , 2017, Shock.

[26]  G. Salekdeh,et al.  Advanced glycation end‐products produced systemically and by macrophages: A common contributor to inflammation and degenerative diseases , 2017, Pharmacology & therapeutics.

[27]  Xiuwen Wu,et al.  Elevated Levels of Plasma Mitochondrial DNA Are Associated with Clinical Outcome in Intra-Abdominal Infections Caused by Severe Trauma. , 2017, Surgical infections.

[28]  B. Brumback,et al.  Human Myeloid-derived Suppressor Cells are Associated With Chronic Immune Suppression After Severe Sepsis/Septic Shock , 2017, Annals of surgery.

[29]  L. Moldawer,et al.  Sepsis Pathophysiology, Chronic Critical Illness, and Persistent Inflammation-Immunosuppression and Catabolism Syndrome , 2017, Critical care medicine.

[30]  R. Hotchkiss,et al.  Frontline Science: Defects in immune function in patients with sepsis are associated with PD‐1 or PD‐L1 expression and can be restored by antibodies targeting PD‐1 or PD‐L1 , 2016, Journal of leukocyte biology.

[31]  R. Hotchkiss,et al.  Comparison of monocyte human leukocyte antigen-DR expression and stimulated tumor necrosis factor alpha production as outcome predictors in severe sepsis: a prospective observational study , 2016, Critical Care.

[32]  S. Brakenridge,et al.  The long-term burden of severe sepsis and septic shock: Sepsis recidivism and organ dysfunction , 2016, The journal of trauma and acute care surgery.

[33]  E. Sherwood,et al.  Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression. , 2016, Pharmacological research.

[34]  Peter J. Murray,et al.  Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards , 2016, Nature Communications.

[35]  R. Bellomo,et al.  Timing of onset and burden of persistent critical illness in Australia and New Zealand: a retrospective, population-based, observational study. , 2016, The Lancet. Respiratory medicine.

[36]  R. Hotchkiss,et al.  Sepsis and septic shock , 2016, Nature Reviews Disease Primers.

[37]  P. Pickkers,et al.  Plasma Nuclear and Mitochondrial DNA Levels, and Markers of Inflammation, Shock, and Organ Damage in Patients with Septic Shock , 2016, Shock.

[38]  M. Shankar-Hari,et al.  Evidence for a causal link between sepsis and long-term mortality: a systematic review of epidemiologic studies , 2016, Critical Care.

[39]  W. Gause,et al.  Innate cell communication kick-starts pathogen-specific immunity , 2016, Nature Immunology.

[40]  M. Delano,et al.  Sepsis-induced immune dysfunction: can immune therapies reduce mortality? , 2016, The Journal of clinical investigation.

[41]  J. Lord,et al.  Immunesenescence and inflammaging: A contributory factor in the poor outcome of the geriatric trauma patient , 2015, Ageing Research Reviews.

[42]  Sun-Mee Lee,et al.  DAMPs activating innate immune responses in sepsis , 2015, Ageing Research Reviews.

[43]  J. Minei,et al.  Mitochondrial ROS Induces Cardiac Inflammation via a Pathway through mtDNA Damage in a Pneumonia-Related Sepsis Model , 2015, PloS one.

[44]  Xue Han,et al.  Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. , 2015, The Journal of clinical investigation.

[45]  H. Baker,et al.  A Detailed Characterization of the Dysfunctional Immunity and Abnormal Myelopoiesis Induced by Severe Shock and Trauma in the Aged , 2015, The Journal of Immunology.

[46]  F. Moore,et al.  Persistent inflammatory, immunosuppressed, catabolic syndrome (PICS): A new phenotype of multiple organ failure. , 2015, Journal of advanced nutritional and human metabolism.

[47]  A. Friggeri,et al.  STAT5 phosphorylation in T cell subsets from septic patients in response to recombinant human interleukin‐7: a pilot study , 2015, Journal of leukocyte biology.

[48]  G. Van den Berghe,et al.  Soluble RAGE and the RAGE Ligands HMGB1 and S100A12 in Critical Illness: Impact of Glycemic Control with Insulin and Relation with Clinical Outcome , 2015, Shock.

[49]  W. Chao,et al.  Importance of Toll-like Receptor 2 in Mitochondrial Dysfunction during Polymicrobial Sepsis , 2014, Anesthesiology.

[50]  L. Rydén,et al.  A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in gram‐positive cases , 2014, Journal of leukocyte biology.

[51]  S. Lemeshow,et al.  Surviving Sepsis Campaign: association between performance metrics and outcomes in a 7.5-year study , 2014, Intensive Care Medicine.

[52]  B. Giraudeau,et al.  Circulating Immature Granulocytes With T-Cell Killing Functions Predict Sepsis Deterioration* , 2014, Critical care medicine.

[53]  N. Anstey,et al.  Neutrophils with myeloid derived suppressor function deplete arginine and constrain T cell function in septic shock patients , 2014, Critical Care.

[54]  R. Hotchkiss,et al.  Parallels between cancer and infectious disease. , 2014, New England Journal of Medicine.

[55]  R. Hotchkiss,et al.  Reactivation of Multiple Viruses in Patients with Sepsis , 2014, PloS one.

[56]  M. Heneka,et al.  Long-term cerebral consequences of sepsis , 2014, The Lancet Neurology.

[57]  A. Gabrielli,et al.  Computer versus paper system for recognition and management of sepsis in surgical intensive care , 2014, The journal of trauma and acute care surgery.

[58]  R. Hotchkiss,et al.  Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy , 2013, Nature Reviews Immunology.

[59]  Chibeza C. Agley,et al.  Acute skeletal muscle wasting in critical illness. , 2013, JAMA.

[60]  M. Boermeester,et al.  S100A12 and Soluble Receptor for Advanced Glycation End Products Levels During Human Severe Sepsis , 2013, Shock.

[61]  R. Hotchkiss,et al.  Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis , 2013, Critical Care.

[62]  R. Tompkins,et al.  Development of a Genomic Metric That Can Be Rapidly Used to Predict Clinical Outcome in Severely Injured Trauma Patients* , 2013, Critical care medicine.

[63]  S. Singhal,et al.  Myeloid derived suppressor cells , 2013, Oncoimmunology.

[64]  M. Fleshner,et al.  The inflammasome and danger associated molecular patterns (DAMPs) are implicated in cytokine and chemokine responses following stressor exposure , 2013, Brain, Behavior, and Immunity.

[65]  M. Fleshner Stress-evoked sterile inflammation, danger associated molecular patterns (DAMPs), microbial associated molecular patterns (MAMPs) and the inflammasome , 2013, Brain, Behavior, and Immunity.

[66]  C. Malcus,et al.  Decreased T-Cell Repertoire Diversity in Sepsis: A Preliminary Study* , 2013, Critical care medicine.

[67]  J. Marko,et al.  ATP Hydrolysis Enhances RNA Recognition and Antiviral Signal Transduction by the Innate Immune Sensor, Laboratory of Genetics and Physiology 2 (LGP2)* , 2012, The Journal of Biological Chemistry.

[68]  C. Malcus,et al.  IL-7 Restores Lymphocyte Functions in Septic Patients , 2012, The Journal of Immunology.

[69]  R. Hotchkiss,et al.  Interleukin-7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis. , 2012, The Journal of infectious diseases.

[70]  Janet S. Lee,et al.  STAT1-Regulated Lung MDSC-like Cells Produce IL-10 and Efferocytose Apoptotic Neutrophils With Relevance In Resolution of Bacterial Pneumonia , 2012, Mucosal Immunology.

[71]  R. Hotchkiss,et al.  A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis , 2012, Critical Care.

[72]  L. Moldawer,et al.  Persistent inflammation and immunosuppression: A common syndrome and new horizon for surgical intensive care , 2012, The journal of trauma and acute care surgery.

[73]  H. Wunsch,et al.  Population Burden of Long‐Term Survivorship After Severe Sepsis in Older Americans , 2012, Journal of The American Geriatrics Society.

[74]  M. Lederman,et al.  Effects of Recombinant Human Interleukin 7 on T-Cell Recovery and Thymic Output in HIV-Infected Patients Receiving Antiretroviral Therapy: Results of a Phase I/IIa Randomized, Placebo-Controlled, Multicenter Study , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[75]  Xin Lin,et al.  C-type lectin receptor-induced NF-κB activation in innate immune and inflammatory responses , 2012, Cellular and Molecular Immunology.

[76]  R. Hotchkiss,et al.  Immunosuppression in patients who die of sepsis and multiple organ failure. , 2011, JAMA.

[77]  John D. Storey,et al.  A genomic storm in critically injured humans , 2011, The Journal of experimental medicine.

[78]  B. McKinley,et al.  Computer protocol facilitates evidence-based care of sepsis in the surgical intensive care unit. , 2011, The Journal of trauma.

[79]  T. Fry,et al.  Harnessing the biology of IL-7 for therapeutic application , 2011, Nature Reviews Immunology.

[80]  B. Allaouchiche,et al.  Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients , 2011, Critical care.

[81]  Lyle L. Moldawer,et al.  A Paradoxical Role for Myeloid-Derived Suppressor Cells in Sepsis and Trauma , 2011, Molecular medicine.

[82]  L. Kao,et al.  The epidemiology of sepsis in general surgery patients. , 2011, The Journal of trauma.

[83]  Yan Zhang,et al.  Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients , 2011, Critical care.

[84]  Fei Wang,et al.  Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis , 2011, Critical care.

[85]  M. Saleh,et al.  The Inflammasomes: Molecular Effectors of Host Resistance Against Bacterial, Viral, Parasitic, and Fungal Infections , 2010, Front. Microbio..

[86]  Yan Zhang,et al.  PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction , 2010, Critical care.

[87]  Je-in Youn,et al.  The biology of myeloid‐derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity , 2010, European journal of immunology.

[88]  Greg Noel,et al.  A Ribonucleotide Reductase Inhibitor Reverses Burn-Induced Inflammatory Defects , 2010, Shock.

[89]  Shannon S Carson,et al.  One-Year Trajectories of Care and Resource Utilization for Recipients of Prolonged Mechanical Ventilation , 2010, Annals of Internal Medicine.

[90]  R. Hotchkiss,et al.  Delayed administration of anti‐PD‐1 antibody reverses immune dysfunction and improves survival during sepsis , 2010, Journal of leukocyte biology.

[91]  N. Voirin,et al.  Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock , 2010, Intensive Care Medicine.

[92]  J. Magarian Blander,et al.  Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function , 2010, The Journal of experimental medicine.

[93]  S. Akira,et al.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors , 2010, Nature Immunology.

[94]  P. Pronovost,et al.  Long-term mortality and quality of life in sepsis: A systematic review* , 2010, Critical care medicine.

[95]  W. McGee,et al.  Expectations and outcomes of prolonged mechanical ventilation. , 2010, Critical care medicine.

[96]  R. Hotchkiss,et al.  IL-7 Promotes T Cell Viability, Trafficking, and Functionality and Improves Survival in Sepsis , 2010, The Journal of Immunology.

[97]  A. Coyle,et al.  HMGB1 and RAGE in inflammation and cancer. , 2010, Annual review of immunology.

[98]  Kaoru Tominaga,et al.  Activation of innate immune antiviral response by NOD2 , 2009, Nature Immunology.

[99]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[100]  D. Venzon,et al.  Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets , 2008, The Journal of experimental medicine.

[101]  Graham R. Foster,et al.  Interferons at age 50: past, current and future impact on biomedicine , 2007, Nature Reviews Drug Discovery.

[102]  E. Wherry,et al.  Molecular signature of CD8+ T cell exhaustion during chronic viral infection. , 2007, Immunity.

[103]  L. Moldawer,et al.  MyD88-dependent expansion of an immature GR-1+CD11b+ population induces T cell suppression and Th2 polarization in sepsis , 2007, The Journal of experimental medicine.

[104]  L. Moldawer,et al.  Increased Natural CD4+CD25+ Regulatory T Cells and Their Suppressor Activity Do Not Contribute to Mortality in Murine Polymicrobial Sepsis1 , 2006, The Journal of Immunology.

[105]  Philip J. R. Goulder,et al.  PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression , 2006, Nature.

[106]  S. Rosenberg,et al.  IL-7 Administration to Humans Leads to Expansion of CD8+ and CD4+ Cells but a Relative Decrease of CD4+ T-Regulatory Cells , 2006, Journal of immunotherapy.

[107]  G. Freeman,et al.  Restoring function in exhausted CD8 T cells during chronic viral infection , 2006, Nature.

[108]  L. Moldawer,et al.  The origins of cachexia in acute and chronic inflammatory diseases. , 2006, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[109]  M. Belosevic,et al.  Regulation of myeloid development and function by colony stimulating factors. , 2004, Developmental and comparative immunology.

[110]  T. Okazaki,et al.  PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver , 2003, The Journal of experimental medicine.

[111]  J. Vincent,et al.  Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis* , 2003, Critical care medicine.

[112]  R. Flavell,et al.  Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 , 2001, Nature.

[113]  S. Akira,et al.  The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5 , 2001, Nature.

[114]  S. Akira,et al.  A Toll-like receptor recognizes bacterial DNA , 2000, Nature.

[115]  S. Belknap,et al.  A Randomized Controlled Trial of Filgrastim as an Adjunct to Antibiotics for Treatment of Hospitalized Patients with Community-Acquired Pneumonia , 1998 .

[116]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[117]  K. Asadullah,et al.  Monocyte deactivation in septic patients: Restoration by IFN-γ treatment , 1997, Nature Medicine.

[118]  K. Asadullah,et al.  Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. , 1997, Archives of internal medicine.

[119]  I. Chaudry,et al.  IMMUNE DYSFUNCTION IN MURINE POLYMICROBIAL SEPSIS: MEDIATORS, MACROPHAGES, LYMPHOCYTES AND APOPTOSIS , 1996, Shock.

[120]  S. Streat,et al.  Sequential changes in the metabolic response in critically injured patients during the first 25 days after blunt trauma. , 1996, Annals of surgery.

[121]  F. Lewis,et al.  Effect of interferon gamma on infection-related death in patients with severe injuries. A randomized, double-blind, placebo-controlled trial. , 1994, Archives of surgery.

[122]  J. Cavaillon,et al.  Dysregulation of in vitro cytokine production by monocytes during sepsis. , 1991, The Journal of clinical investigation.

[123]  L. Moldawer,et al.  Dysregulated myelopoiesis and hematopoietic function following acute physiologic insult , 2018, Current opinion in hematology.

[124]  S. Brakenridge,et al.  Chronic Critical Illness: Application of What We Know. , 2018, Nutrition in clinical practice.

[125]  S. Vieira,et al.  Chronic critical illness: are we saving patients or creating victims? , 2017, Revista Brasileira de terapia intensiva.

[126]  T. Waldmann,et al.  Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  Jacques Duranteau,et al.  Oxidative stress and endothelial dysfunction during sepsis. , 2011, Frontiers in bioscience.

[128]  M. Singer Metabolic failure. , 2005, Critical care medicine.

[129]  Joseph T. Murphy,et al.  Reactive oxygen species mediate endotoxin-induced human dermal endothelial NF-kappaB activation. , 2003, The Journal of surgical research.

[130]  C. Janeway,et al.  Innate immune recognition. , 2002, Annual review of immunology.

[131]  S. Belknap,et al.  A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. CAP Study Group. , 1998, The Journal of infectious diseases.

[132]  K. Asadullah,et al.  Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. , 1997, Nature medicine.